Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $59,595
Award facts
- Contract value 100% obligated
- $59,595.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $59,595 delivery order to DMS Pharmaceutical Group Inc. on January 5, 2026, for the supply of Entyvio 300 mg vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, is the sole awardee with no identified subcontractors. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating DMS competed in unrestricted federal procurement. The delivery order is scheduled for ultimate completion by January 6, 2026, reflecting the expedited nature typical of pharmaceutical supply replenishment orders.
This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated SPE2DR, which carries a $499.999 billion ceiling value through December 31, 2036. The parent contract positions DMS as a critical regional pharmaceutical supplier supporting Department of Defense healthcare operations worldwide, authorized to fulfill recurring medical supply needs across military medical facilities. The delivery order for Entyvio represents one component of the company's broader role within the PPV-G GEN V program, which is part of the Defense Logistics Agency's $30.3 billion pharmaceutical acquisition strategy designed to ensure consistent access to branded and generic pharmaceuticals, biologics, and medical consumables across the federal military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FQWH9?
SPE2DR26FQWH9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FQWH9 worth?
The government has obligated $59,595 on SPE2DR26FQWH9.
Is contract SPE2DR26FQWH9 an order under another contract?
Yes. SPE2DR26FQWH9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH9 competed?
The extent of competition for SPE2DR26FQWH9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award